Clinical Trials Logo

Filter by:
NCT ID: NCT05907005 Not yet recruiting - Stroke Clinical Trials

Instant Message-delivered Early Psychological Intervention in Stroke Family Caregivers

EPI
Start date: July 24, 2023
Phase: N/A
Study type: Interventional

Psychological distress including depression and anxiety is a major component of caregiver stress, and its negative impact on caregivers' health and well-being has been established in the literature. A recent meta-analysis reported the prevalence of depression and anxiety in stroke caregivers as 40.2% and 21.4% respectively. An evidence profile report by the World Health Organization(WHO) has emphasised that psychological support is crucial in helping caregivers in the community to continue caring for individuals with long-term disabilities, such as stroke patients. Therefore, early psychological intervention (EPI) is crucial to improve the management and prognosis of an individual who are facing stressful events like caregiving. The main aim of this study is to prevent or alleviate the significant psychological consequences in carers resulting from stroke events in family members. Internet-delivered cognitive-behavioural therapy (iCBT) is delivered as an ecological momentary intervention (EMI) to support the clients to engage in cognitive reframing and empower them with proper knowledge, skills and attitudes to make behavioural changes.

NCT ID: NCT05899946 Not yet recruiting - Cannabis Clinical Trials

An Integrated Program to Promote Anti-cannabis Messages

Start date: September 2023
Phase: N/A
Study type: Interventional

The number of youngsters abusing cannabis is surging, the public health consequences caused by cannabis can be unpredictable. Educating the public especially the young population about cannabis need to be highlighted. To successfully promote anti-cannabis messages to youngsters and prevent them from taking cannabis, the involvement of their parents and modern technology such as robots can be helpful. This project aims to educate the young population and their parents about cannabis, particularly its legal consequences and clarifying their misconceptions.

NCT ID: NCT05894668 Not yet recruiting - Renal Stone Clinical Trials

Perioperative Parameter and Treatment Outcomes of ECIRS in Asia

Start date: June 1, 2023
Phase:
Study type: Observational

This is an observational, international, multicenter, cohort study, prospectively collecting clinical data registry on consecutive patients with urinary stone undergoing ECIRS.

NCT ID: NCT05864339 Not yet recruiting - Smoking Cessation Clinical Trials

Efficacy of a Designed Empathy Course

Start date: May 25, 2023
Phase: N/A
Study type: Interventional

This proposed study aims to develop a designed empathy course intervention during the smoking cessation counseling (SCC) training for master nursing students at the University of Hong Kong. The objectives are: 1. To increase master nursing students' empathy towards smokers. 2. To increase master nursing students' self-efficacy towards SCC. 3. To improve master nursing students' attitude towards SCC; 4. To increase master nursing students' use of 5As counseling skill(Ask, Advise, Assess, Assist, and Arrange) during their practice.

NCT ID: NCT05825040 Not yet recruiting - Mental Health Issue Clinical Trials

Randomized Controlled Trial on Precision Mental Health

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The current study aims to evaluate the effectiveness of different online psychological interventions, including guided and unguided transdiagnostic cognitive behavioural therapy, and unguided mindfulness-based intervention, on mental well-being in comparison to waitlist control. It is hypothesized that participants with the guided psychological intervention will show (H1) a greater reduction in mental health symptoms, and (H2) better mental well-being compared with participants with unguided psychological intervention and the control condition.

NCT ID: NCT05804201 Not yet recruiting - Clinical trials for Malignant Biliary Obstruction

EUS-guided Hepatico-gastrostomy With Hot Giobor

Start date: June 15, 2023
Phase: N/A
Study type: Interventional

Endoscopic ultrasonography-guided hepaticogastrostomy (EUS-HGS) is a method of obtaining biliary drainage in patients with failed or difficult endoscopic retrograde cholangiopancreatography (ERCP). The reason for failure of ERCP can be due to gastric outlet obstruction or failed cannulation. HGS involves placement of a stent between the bile duct and the stomach under the guidance of endoscopic ultrasound to create a biliary drainage route similar to surgery. The overall reported success rate is 94% with an overall complication rate of 14%. The most common complications include pneumoperitoneum (air leaking into the abdomen) and bile leak. Both complications are usually managed conservatively. EUS-gudied HGS has been commonly performed but the type of stent used for the procedure is still under evolution. A specific stent is needed to prevent complications. The most commonly used stent in HK is a hybrid stent where the liver portion is uncovered to avoid stent migration and the rest of the stent is covered to avoid bile leakage and pneumoperitonum. This stent is already available and is called the Giobor stent. However, in order to use this stent, during the EUS procedure, the bile duct needs to be first punctured by a EUS needle, then a guidewire passed, then dilate the tract with an energy deviced 6Fr cytotome, then the stent can be passed. This process is cumbersome and increase the chance of complications during exchange of the devices. A newly developed stent that is cautery-fitted has been developed. The use of this stent shortens the steps of stent application. The current study aims to evaluate the feasibility and safety of a novel stent that is cautery-fitted designed for performance of EUS-HGS (Niti-S HOT Giobor).

NCT ID: NCT05798884 Not yet recruiting - Colorectal Cancer Clinical Trials

Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients

Start date: May 2023
Phase: N/A
Study type: Interventional

In this study, a 24-week randomized, sham-controlled, single-blind, multicenter clinical trial will be conducted to explore the effect of electroacupuncture for prevention and treatment of both acute and chronic neurotoxicity through both clinical and biological indicators.

NCT ID: NCT05796622 Not yet recruiting - Behaviors, Health Clinical Trials

Evaluating an Innovative HIV Self-testing Service With Counseling Provided by a Chatbot

Start date: April 16, 2023
Phase: N/A
Study type: Interventional

A parallel-group non-inferiority randomized controlled trial will then be conducted to evaluate the performance of HIVST-Chatbot. A total of 528 Hong Kong Chinese speaking men who have sex with men (MSM) aged ≥18 years who have access to live-chat applications are recruited from multiple sources. Those who are diagnosed as HIV positive are excluded. Participants are 1:1 randomized into the intervention group (n=264) or the control group (n=264). The research team will implement the HIVST-Chatbot (HIVST services with real-time counselling provided by a fully-automated artificial intelligence Chatbot) in the intervention group and HIVST-OIC (HIVST with real-time counselling provided by trained administrators) in the control group. Participants completed two telephone surveys at baseline and six months afterwards.

NCT ID: NCT05766124 Not yet recruiting - Pleural Infection Clinical Trials

Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)

Start date: June 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Objectives: A pilot study to compare the therapeutic and safety profiles between low(2.5mg) and standard(10mg) doses of intrapleural tissue plasminogen activator(tPA) in uncontrolled pleural infection. The study design will be tested for its trialability. Hypothesis: 2.5mg tPA has comparable therapeutic efficacy and less bleeding complications to 10mg tPA. Design and subjects: A pilot, single-centre, two-arm, double-blinded, randomized controlled trial(RCT) which includes subjects with uncontrolled pleural infection, with follow-up till 90 days after hospital discharge. Interventions: Recruited subjects will be randomized in 1:1 ratio to receive a maximum of 6 doses of intrapleural tPA starting at either 2.5mg or 10mg. A clinical decision is allowed at the third dose to continue with the assigned dose or escalate to 10mg to complete the course based on the clinical response, without breaking the blinding. Main outcome measures: The primary outcome is survival at 90 days and without the need for surgical intervention. Secondary outcomes include the need for additional pleural interventions, number of decisions to choose 10mg intrapleural tPA at the third dose, clinical and radiographic response after the treatment course, safety profiles especially bleeding complications, and the number and reason for protocol violation. Data analysis and expected results: Data will be analyzed on an intention-to-treat basis for all randomized subjects. The clinical outcomes will be compared with a regression model built to adjust for confounding covariates. The data on therapeutic efficacy and bleeding complications will inform the power calculation of sample size in subsequent full-scale multicentred RCT incorporating the current study design.

NCT ID: NCT05748210 Not yet recruiting - Oncology Clinical Trials

A Symptom Management Application for Children at the Early Stage of Cancer Survivorship and Their Caregivers

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The goal of this randomized controlled trial is to examine the efficacy of the mHealth app in improving symptoms experienced by children in the early stage of cancer survivorship, including physical function, anxiety, depressive symptoms, fatigue, peer relationships, and pain interference, and at improving the quality of life (QoL) of the children's primary caregivers The main question it aims to answer is whether survivors who receive the symptom management mHealth app intervention will report improved symptoms, i.e., improved physical function; lower levels of anxiety, depressive symptoms, and fatigue; better peer relationships; and lower pain interference 3 months after starting the intervention. Additionally, we hypothesized that the primary caregivers (either the mother or father) would report an improved QoL 3 months after starting the intervention. Participants in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. They are required to complete questionnaires at baseline (during medical follow-up), 1, 2, and 3 months (via electronic-based systems in the mobile app) Besides, semi-structured interviews and will be conducted to examine the usability, feasibility, and acceptability of the intervention.